CDSCO Panel Recommends Phase III Trial of Tetanus Vaccine by Indian Immunologicals in Pregnant Women

Published On 2025-06-04 10:03 GMT | Update On 2025-06-04 10:03 GMT

New Delhi: The Subject Expert Committee (SEC) for Vaccines under the Central Drugs Standard Control Organisation (CDSCO) has recommended the conduct of a Phase III clinical trial for the Tetanus Vaccine (Adsorbed, I.P.) developed by Indian Immunologicals Limited, Hyderabad.

The recommendation came during the SEC meeting held on May 22, 2025, through hybrid mode, where the panel reviewed and re-deliberated the firm’s proposal [File No. BIO/CT/23/000129].

Indian Immunologicals presented crucial data in response to earlier observations made by the SEC during its meeting on February 5, 2024. The submission included:

Developmental and Reproductive Toxicity (DART) study reports conducted in rats and rabbits.

Post-marketing safety data of the marketed vaccine.

Published literature on the vaccine's safety and efficacy.

After detailed examination of the submitted documentation and data, the expert panel gave the go-ahead to conduct the Phase III clinical trial specifically in healthy pregnant women, as per the protocol submitted by the company.

Also Read: Indian Immunologicals, ICMR to develop Zika Vaccine

Indian Immunologicals Limited (IIL) is a leading biotechnology company based in Hyderabad, India, and a subsidiary of the National Dairy Development Board (NDDB). Established in 1982, IIL is known for its significant contributions to human and animal health through the development and production of high-quality vaccines. The company manufactures a wide range of vaccines, including those for rabies, hepatitis, measles, and tetanus, and is recognized for its strong R&D capabilities and affordable healthcare solutions.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Parthika Patel

Parthika Patel has completed her Graduated B.Pharm from SSR COLLEGE OF PHARMACY and done M.Pharm in Pharmaceutics. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

CDSCO Panel Recommends Phase III Trial of Tetanus Vaccine by Indian Immunologicals in Pregnant Women

Similar News

Cocrystals of Approved APIs to Be Treated as New Drugs, Clarifies CDSCO

Intas Pharma Secures CDSCO Panel Approval for Post-Marketing Study of Tacrolimus Enema

CDSCO Panel Asks Wockhardt to Revise Phase III Study Protocol for Nafithromycin, Seeks Dosing, Control Arm Changes

Eris Lifesciences Secures CDSCO Panel Nod to Conduct BE Study on Dapagliflozin, Pioglitazone, Metformin FDC

AstraZeneca's Proposal to Increase Sample Size in Zibotentan-Dapagliflozin Global Trial Gets SEC Nod

CDSCO Panel Nod To Phase I Clinical Trial of Anticancer Drug Bevacizumab by Jeevan Scientific

Fixed Dose Combination of Metformin-Voglibose Now CDSCO Approved

Insufficient Efficacy, Safety Data: CDSCO Panel Rejects Zydus' Phase III CT Waiver Request for Voclosporin